复发或难治性非小细胞肺癌的化疗进展  

Latest developments in chemotherapy for patients with relapsed or refractory non-small cell lung cancer

作　　者：王宏羽[1] 张湘茹[1] 屈风莲[1] 储大同[1] 孙燕[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《癌症进展》2005年第3期237-242,共6页Oncology Progress

摘　　要：对含铂类药物治疗后复发的非小细胞肺癌,单药泰索帝为标准的二线化疗药物,可明显延长病人的生存时间及改善生活质量。一项泰索帝的Ⅲ期随机对照研究证实,多靶点叶酸抑制剂的抗代谢药Alimta二线化疗治疗非小细胞肺癌,其疗效、中位生存时间及1年生存率与泰索帝相似,可替代泰索帝成为晚期NSCLC的二线化疗药物。泰索帝与健择、卡铂、伊立替康、EGFR-TK抑制剂及抗血管生成剂联合化疗,有一定的疗效。TXT为复发的NSCLC常用的二线标准治疗方案。Alimta为备用的二线治疗方案。Iressa单药对铂类及泰索帝失败后的晚期非小细胞肺癌仍然有效。Single agent docetaxel as the standard second line treatment was reported to show promising activity leading to the improved survival and quality of life in NSCLC patients recurring after platinum-based chemotherapy.Pemetrexed disodium,a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway,is simlar to TXT in overall response rate,median survival time and 1 year survival rate in a randomized phase Ⅲ trail of pemetrexed versus docetaxal in patients with NSCLC previously treated with chemptherapy,pemetrexed should be considered a standard treatment option for second line NSCLC.The combination chemotherapy of gemcitabine,carboplatin,CPT-11,gefitinib and thalidomide with docetaxel respectively are active in NSCLC.Single agent docetaxel represents the standard second line treatment in relapsed NSCLC patients.Pemetrexed disodium should be considered a standard treatment option for second-line NSCLC.Iressa as monotherapy after failure of both platinum-based and docetaxel therapies is still active in NSCLC.

关 键 词：非小细胞肺癌 二线化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]